AMG 193, Methylthioadenosine (MTA) Cooperative Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, Alone and in Combination With Docetaxel in Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors

Phase 1

Recruiting

Conditions: Advanced MTAP-null Solid Tumors

Registration Number: JPRN-jRCT2041220005

Lead Sponsor: Iizumi Sakura

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 527

Inclusion Criteria

1. Participant has provided informed consent/assent before initiation of any study specific activities/procedures.
2. Age >= 18 years.
3. Evidence of homozygous loss of cyclin dependent kinase inhibitor 2A (CDKN2A) (null) (Parts 1a, 1j, 1k, and 2a only) and/or methylthioadenosine phosphorylase (MTAP) (null) in the tumor tissue or blood (Parts 1a to 1k, Parts 2a and 2b) or lost MTAP expression in the tumor tissue (Parts 1a to 1k, Parts 2a and 2b).
4. Histologically confirmed metastatic or locally advanced solid tumor not amenable to curative treatment with surgery and/or radiation.
5. Able to swallow and retain orally (PO) administered study treatment and willing to record daily adherence to investigational product.
6. Disease measurable as defined by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1).
7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
8. Adequate hematopoietic function per local laboratory.
9. Adequate renal function per local laboratory.
10. Adequate glucose control per local laboratory (Part 1 only).
11. Adequate liver function per local laboratory.
12. Adequate coagulation parameters.
13. Adequate pulmonary function.
14. Adequate cardiac function.
15. Minimum life expectancy of 12 weeks as per investigator judgement.
16. A total of 25 slides of archived tumor tissue (formalin-fixed, paraffin-embedded [FFPE] sample collected within 5 years) or an archival block must be available.
17. For Part 1f (MTAP-null or lost MTAP expression HNSCC): Must be willing to undergo tumor biopsy.
18. For Part 1abackfill: Must be willing to undergo tumor biopsy, before start of treatment (archival sample acceptable if obtained with 6 months of enrollment and subject has not received any other treatment since sample was obtained) and while on treatment.
19. Part 1i: Enrollment criteria for Part 1i are to match the criteria of the expansion arm from which the indication was selected.
20. For DSPS study (Part 1j): Must be willing to participate in DSPS substudy (US sites only).

Food Effect Substudy (Part 1k): Specific Inclusion Criteria
21. Subject able and willing to eat a standardized high-fat, high-caloric meal
22. Subject able and willing to fast for >= 6 hours

Exclusion Criteria

1. Spinal cord compression or untreated brain metastases or leptomeningeal disease.
2. History of other malignancy within the past 2 years.
3. Any evidence of current interstitial lung disease
4. Active infection.
5. Evidence of active severe acute respiratory syndrome coronavirus 2 (SARS-COV2) infection.
6. History of arterial thrombosis.
7. Myocardial infarction and/or symptomatic congestive heart failure.
8. Gastrointestinal tract disease.
9. History of bowel obstruction, abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess
10. History of solid organ transplant.
11. Diagnosis of Congenital Short QT Syndrome.
12. Major surgery
13. Anti-tumor therapy within 28 days of study day 1, unless anti-tumor therapy is a therapy with 5 times the half-life being shorter than 28 days
14. Prior treatment with an methionine adenosyltransferase 2a (MAT2A) inhibitor or a protein arginine methyltransferase 5 (PRMT5) inhibitor.
15. Prior treatment with docetaxel (Part 2 only)
16. Prior irradiation to >25% of the bone marrow.
17. Therapeutic or palliative radiation therapy within 2 weeks of study day 1.
18. Live vaccine therapy within 4 weeks before study drug administration.
19. Use of therapeutic anti-coagulation for treatment of active thromboembolic events.
20. Use of prescription medications that are known strong inducers of cytochrome P450 3A4 (CYP3A4) within 14 days or 5half-lives (whichever is longer) before study day 1
21.Unresolved toxicity from prior anti-cancer therapy.
22. Currently receiving treatment in another investigational device or drug study.
23. Known positive test for Human Immunodeficiency Virus (HIV).
24. Positive hepatitis B surface antigen
25. positive hepatitis C virus ribonucleic acid (RNA) by polymerase chain reaction (PCR)
26. Female participants of childbearing potential unwilling to use protocol specified method of contraception.